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The authors present a case report of a patient with breast cancer diagnosed in 2005, treated
with conservative surgery, adjuvant chemotherapy and radiotherapy, followed by hormonal
therapy until 2010, who relapsed under the form of inﬂammatory breast cancer in 2011.
After  tumor progression detected during primary systemic therapy, a concurrent radiation
and  radiosensitizing chemotherapy were proposed. There was a signiﬁcant clinical response
to  this treatment, enabling curative chance with total mastectomy. The histological exam-
ination of the breast and regional lymph nodes revealed a complete response, since there
was no evidence of residual tumor.
There are few reports concerning concurrent radiotherapy and chemotherapy in locallyhemotherapy
eirradiation
advanced breast cancer, but it could be a suitable “loco regional rescue therapy” to further
reduce tumor progression and allow curative surgery. Study of this treatment strategy in
randomized clinical trials is warranted.
©  2013 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
of tumor response. Thus, it is not only rational, but also cur-.  Background
nﬂammatory breast cancer (IBC) is a rare subgroup of locally
dvanced breast cancer (LABC) that presents particular man-
gement challenges. This biologically aggressive disease,
linically diagnosed, is more  frequently seen in women that
ave never had breast cancer, but it can also develop in a
reast that contains a known tumor or that has been previ-
usly treated.1
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The prognosis of patients with LABC has improved over the
last 2 decades, with the recognition of the efﬁcacy of a multi-
modality approach. Advances in neoadjuvant chemotherapy
(CT) in this setting include not only earlier treatment of
sub-clinical distant micrometastases and primary tumor
downstaging, but also the possibility of in vivo assessmententil do Porto, E.P.E. Rua Doutor António Bernardino de Almeida,
rent practice, to apply this approach in unresectable LABC.2
According to current guidelines, preoperative CT consisting
of anthracycline based regimens with or without taxane are
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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now recommended. Her-2-positive patients should receive an
initial CT program incorporating preoperative trastuzumab.
For operable tumors after CT, this treatment should be fol-
lowed by local therapy consisting of total mastectomy or
lumpectomy, with a level I/II axillary lymph node dissection,
when necessary. Both groups are considered to have sufﬁcient
risk of local recurrence to warrant the use of chest wall (or
breast) and supraclavicular node irradiation. Adjuvant ther-
apy may involve completion of planned CT regimen course if
not completed preoperatively, followed by endocrine therapy
in patients with hormone receptor-positive disease. However,
only 10–20% of patients achieve a complete clinical response,
and 50–60%, partial response to induction CT.3–5
For patients whose tumors remain inoperable despite
induction systemic therapy, the optimal management strategy
has not been established. Preoperative radiotherapy (RT) has
been used, but few data are available regarding this approach.
Therefore, this treatment modality has not been widely used
in patients with LABC.
Radiosensitizers are chemical agents that can modify
tumor response to RT. This citotoxic enhancement explains
the ability of chemotherapy to induce lethal effects in tumor
cells and interfere in their capability of repairing DNA dam-
age, when administered together with radiation.6 The beneﬁt
provided by RCT is greater than it would be expected from the
mere  additivity of the independent effects of each modality.6
In fact, concurrent CT and RT have successfully improved
both local control and overall survival (OS) in other cancers
such as naso and oropharynx,7 oesophagus,8 cervix9 and anal
cancer.10 Based on this experience, it is reasonable to exploit
the synergism of this two therapeutic modalities in LABC,
since this approach could allow more  patients to proceed
surgery and improve local control.
2.  Case  report
A 46-year-old premenopausal woman presented with a com-
plaint of a breast mass, located in the right upper outer
quadrant (UOQ). She has been taking oral contraceptives over
the past 15 years. Menarche occurred at the age of 14, and
her ﬁrst pregnancy at 30 (Gravida 2 Para 2 Abortion 0). Family
history was negative for both breast and ovarian cancers.
On physical examination, there was a palpable, non-tender
mass measuring about 2.0 cm in the UOQ of the right breast.
There was no mammilar discharge, but it was possible to iden-
tify skin retraction around the mass. Peripheral lymph nodes
were not palpable. The rest of the examination was within
normal limits.
Mammography showed a high-density mass without cal-
ciﬁcation and an indistinct margin in the UOQ of the right
breast. Ultrasonography revealed a 1.3 cm sized hipoecogenic
mass in the same location. No adenopathies were identiﬁed
in the imagiologic study.
The ﬁne needle aspiration biopsy revealed carcinoma. The
clinical stage was determined to be cT1cN0M0 according to
the AJCC staging system.
The patient had undergone wide excision with nega-
tive margins (>2 mm)  and sentinel lymph node biopsy in
October 2006. The histological diagnosis was Invasive Ductaldiotherapy 1 9 ( 2 0 1 4 ) 65–68
Carcinoma (IDCA), grade III, measuring 2.2 cm plus Extensive
Intraductal Component (EIC), high grade, with micro invasive
foci. Three sentinel lymph nodes were excised, none with
metastasis. Immunohistochemical (IHC) examination showed
the presence of both estrogen receptors (ER) and progesterone
receptors (PgR) in 10% of tumor cells and showed strong mem-
brane staining of HER-2 (3+ score). The pathologic stage was
determined to be pT2N0snM0 (Stage IIA).
The patient received postoperative adjuvant CT consisting
of 6 cycles of 5-ﬂuoruracil, adriamicine and cyclophos-
phamide, between November 2006 and February 2007 (total
dose of 504 mg  of each agent), in combination with the human-
ized monoclonal antibody, trastuzumab (initially 8 mg/kg
followed by 6 mg/kg every 3 weeks), which was maintained
for 1 year.
She also received postoperative adjuvant RT, with total
dose of 50 Gy at 2 Gy/day × 25 fractions to the whole right
breast, with tangencial ﬁelds and 4 MV energy. The boost was
administered with Intersticial Brachitherapy: 20 Gy, 85% of
basal dose to tumor loci, with Iridium-192, at pulsed dose rate.
RT was completed on April 2007.
To complete the treatment, the patient received hormonal
therapy (HT), with tamoxifen, from April 2007 to April 2011.
She also received goserelyn from February 2008 to March 2010.
The patient was kept in follow-up, and there was no evi-
dence of loco-regional or distant recurrence for more  than 4
years.
On April 2011, an erythematous skin lesion was identi-
ﬁed in the right breast, involving both the superior quadrants
and the inferior inner quadrant, occupying a total area of
10 cm × 14 cm.  This was an unresectable lesion, associated
with inﬂammatory signs, namely erythema, pain, warmth and
pitted appearance (peau d’orange) of the right breast. The rest
of the physical examination was within the normal limits.
Mammography showed augmented skin thickness, with-
out an individualized mass, a typical feature of IBC.
The histological examination of the core biopsy revealed
ICDA with involvement of the dermis, and vascular invasion.
ER and PgR were negative, and staining for Her-2 scored 2+.
The patient underwent adequate staging examination
which did not reveal distant disease.
In the presence of this local recurrence, under the form of
IBC, and given its unresectability, the patient received primary
systemic therapy, consisting of docetaxel and carboplatin plus
trastuzumab starting on April 2011. However, in August 2011,
tumor progression was detected after 6 cycles of CT, and treat-
ment was suspended. Posteriorly, it was decided to treat the
patient with concurrent RT and CT. RT was delivered to the
right breast, axilla and supra-clavicular fossa with the Rapid
Arc technique, with total dose of 50 Gy at 2 Gy/day × 25 frac-
tions, and 6 MV Energy. For the last 15 fractions, radiation was
delivered  using “bolus”, a tissue equivalent material to ensure
that full radiation dose was reaching the skin. Concomitantly,
the patient received 5 cycles of docetaxel (35 mg/m2, weekly).
No severe adverse event above grade 3 skin toxicity was
seen.A signiﬁcant clinical response to concurrent RT and CT was
detected, and the lesion became operable. The patient under-
went total right mastectomy with immediate reconstruction
in December 2011.
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Histological examination of the operative specimen did not
how any residual carcinoma. The patient continued treat-
ent with trastuzumab and today remains without evidence
f loco-regional or distant recurrence.
.  Discussion
he use of neoadjuvant CT has become a standard of care
or the management of LABC, including IBC. This treatment
ourse enhances the possibility of surgery.7,11,12 Neverthe-
ess, it is now recognized that a proportion of breast cancers
ay be resistant or develop resistance to the chemothera-
eutic agents initially used for their treatment.13 This group
f patients will never respond to treatment, with poor loco-
egional control, impossible surgical resection, increased risk
f distant metastases and bad quality of life. Approximately
0–40% of patients who achieve clinical response enabling
urgical resection develop loco-regional relapse. Addition-
lly, even though tumor progression under neoadjuvant
T is uncommon, it is clearly associated with a dismal
rognosis.14–16
Treatment options for loco-regional recurrences are
imited. CT might not be effective in previously irradiated
issue, because a decreased perfusion can be expected due
o radiation-induced ﬁbrosis.17 This factor might have con-
ributed to the absence of response to neoadjuvant CT veriﬁed
n our patient, who  has shown tumor progression during this
reatment. Therefore, concurrent RT and CT were proposed.
here are few reports concerning this strategy in LABC, but
t could be a suitable “loco regional rescue therapy” to fur-
her reduce tumor progression and allow curative surgery,
hile maintaining systemic therapy. There are several poten-
ial advantages of this combination in the treatment of breast
ancer, including earlier RT treatment, shorter duration of
herapy, and synergistic activity between CT and RT, with
mproved efﬁcacy.18,19
Retreatment with a second course of RT to the breast is to
e used with caution as increased toxicity of skin and subcu-
aneous tissue is feared. Nevertheless, in recent years, several
nvestigators reported on reirradiation. Data on more  than
00 patients reirradiated for recurrent breast cancer, either
lone or in combination with CT, endocrine treatment and/or
yperthermia, have so far been published. According to these
tudies, reirradiation is feasible and safe, at least within the
rst ﬁve years after treatment, with low to modest side effects
ffering a second curative chance.20
The published studies using concurrent RT and CT show
athologic complete response rates of ∼35%.21–23 In two con-
ecutive phase I/II trials, 33 patients with unresectable LABC,
ncluding IBC or locally recurrent disease were treated with
oncurrent CT-RT. CT consisted of either continuous infu-
ion or bolus paclitaxel with or without vinorrelbine, using a
ovel week on/week off (WO/WO) treatment schedule. This
eport demonstrated that concomitant paclitaxel-based CT
nd high-dose RT followed by mastectomy is an aggressive,
ut well tolerated treatment strategy. To the best of our
nowledge, the pathologic response rate of 47% for initially
nresectable Stage IIIB/C breast cancer seen in this studyiotherapy 1 9 ( 2 0 1 4 ) 65–68 67
represents the highest pathologic response rate reported in
the literature.19
Other combinations have been assessed in LABC deemed
inoperable at diagnosis or considered refractory to neoad-
juvant CT. The safety of combining vinorelbine/5FU and
RT has already been evaluated and validated in a phase
II trial.24 These authors found three pathologic complete
response-associated factors: histological grade 3; absence
of hormonal receptors, and high mitotic index.24 Here,
all patients have been pretreated with anthracycline or
taxane based pre-operative CT. This treatment could be
expected to increase toxicity as a result of the syner-
gistic effect of cell damage and apoptosis. However, in
such a setting, “rescue” RT-CT was well tolerated with
grade 2 skin toxicity as the most severe acute side
effect.
Radiation pneumonitis has been a relatively rare prob-
lem of adjuvant therapy. Concurrent CT has been associated
with higher rates of this complication. Other potentiating
factors include addition of nodal irradiation, the extent of
lung exposure to radiation, and underlying lung disease.18
A retrospective analysis at the Massachusetts General Hos-
pital evaluated the risk of pneumonitis in women who
received adriamycin and cyclophosphamide with or with-
out subsequent paclitaxel, with concurrent or sequential RT.
Forty-one women were identiﬁed who had received adju-
vant RT and paclitaxel, roughly half of whom received
concurrent, and half sequential treatment. Paclitaxel was
associated with a 15% risk of pneumonitis, compared with
1% risk in historical experience among women not treated
with paclitaxel.25 These results were not veriﬁed in other
recent studies. Investigators from the University of Wash-
ington reported on a retrospective study of 44 women who
had received either paclitaxel or docetaxel with concurrent
radiation. There was no reported radiation pneumonitis in
this study.26 A prospective study from California reported
on 24 patients treated with AC followed by paclitaxel with
concurrent RT, and no pneumonitis was encountered.27
Formenti and colleagues reported a trial of 44 T3-4N0-3
breast cancer patients treated with neoadjuvant RT (45–50 Gy)
with concomitant twice-weekly paclitaxel (30 mg/m2). A 16%
pathological response rate was achieved with no cases of radi-
ation pneumonitis.28
Our patient, treated with docetaxel and concurrent RT
exhibited a very acceptable proﬁle of toxicity: no radiation
pneumonitis was detected, and no more  than grade 3 skin
toxicity was noted.
In conclusion, treatment of LABC, and particularly IBC,
requires a coordinated multidisciplinary approach that should
be individualized according to the tumor features and
response to primary treatment. Although the optimal treat-
ment to this disease remains uncertain, “rescue” taxane based
CT and RT seems active, safe, and feasible as “secondary-
line” neoadjuvant treatment for LABC that are refractory to
standard anthracycline and taxane based neoadjuvant CT. The
results found in a series of randomized clinical trials concern-
ing this strategy support the study of this treatment strategy
in randomized clinical trials, so this approach should be con-
sidered as part of loco-regional therapy for aggressive breast
cancer.
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